Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
NCT02449681 · Rain Oncology Inc · PHASE2 · terminated · last registry update 2023-01-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | – | Registry record, Rain Oncology Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-18Results posted on the registry: University of California, San Francisco, Neratinib + Trastuzumab (NCT03094052)
- 2023-11-13Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Trastuzumab Emtansine (NCT06126640)
- 2023-09-28Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection (NCT06057610)
- 2023-09-15Phase 3 first posted: Biocon Biologics UK Ltd, PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel (NCT06038539)
- 2023-06-28Results posted on the registry: City of Hope Medical Center, pertuzumab + trastuzumab (NCT01730833)
- 2023-06-26Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan + Capecitabine (NCT03523585)
- 2023-06-12Results posted on the registry: National Cancer Institute (NCI), Aromatase Inhibition Therapy + Carboplatin (NCT02003209)
- 2023-05-01Phase 3 first posted: Shanghai JMT-Bio Inc., Recombinant Humanized Bispecific antibody against HER2，KN026 + HB1801 (NCT05838066)
- 2023-04-06Phase 3 first posted: Biocad, BCD-178 + Perjeta (NCT05802225)
- 2023-03-28Phase 3 first posted: Cancer Research UK, Trastuzumab + Pertuzumab (NCT05786716)
- 2023-03-21Results posted on the registry: Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
- 2023-03-09Results posted on the registry: City of Hope Medical Center, Pertuzumab + Trastuzumab (NCT02827877)
- 2023-03-08Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Trastuzumab and neratinib + Trastuzumab and Pertuzumab (NCT05760612)
- 2023-02-16Results posted on the registry: Hoffmann-La Roche, Pertuzumab IV + Trastuzumab IV (NCT04024462)
- 2023-02-10Phase 3 first posted: Cancer Research UK, Alectinib + Atezolizumab (NCT05722886)
- 2023-02-08Results posted on the registry: University of Alabama at Birmingham, Tucatinib + Trastuzumab (NCT03501979)
- 2022-11-29Results posted on the registry: National Cancer Institute (NCI), Afatinib Dimaleate (NCT04439136)
- 2022-11-23Results posted on the registry: MacroGenics, Margetuximab + Trastuzumab (NCT02492711)
- 2022-11-14Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib (NCT05615818)
- 2022-08-04Results posted on the registry: MacroGenics, Margetuximab 10 mg/kg + Margetuximab 15 mg (NCT02689284)
- 2022-07-28Results posted on the registry: City of Hope Medical Center, Lapatinib + Trastuzumab (NCT01273610)
- 2022-07-20Results posted on the registry: City of Hope Medical Center, trastuzumab + ado-trastuzumab emtansine (NCT02226276)
- 2022-07-06Phase 3 first posted: Instituto Nacional de Cancerologia de Mexico, Metformin Hydrochloride (NCT05445791)
- 2022-06-13Phase 3 first posted: Hoffmann-La Roche, Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) + Pertuzumab IV (NCT05415215)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision